Mylan gets tentative USFDA nod for generic of Eli Lilly lung cancer drug Alimta

Alimta is Lilly's third biggest-selling drug. The Indianapolis-based drugmaker reported second-quarter sales of $577.8 million for the medicine.

U.S: The U.S. Food and Drug Administration on Thursday granted Mylan NV tentative approval for its generic version of Eli Lilly & Co's lung cancer drug Alimta.

A tentative approval generally signals that the FDA has signed off on the company's marketing application, but that it cannot sell the medicine until the U.S. patents have expired.

Lilly stands to lose U.S. patent protection on the chemotherapy drug, known generically as pemetrexed, in 2022.

Read Also: Novo Nordisk files suit against Mylan to block entry of generic Victoza drug in US

Earlier this month, Lilly won a federal appeals court decision protecting its patent from copycat drugs by Pfizer Inc and India's Dr Reddy's Laboratories Ltd.

Read Also: Lawmakers push Mylan, Teva Pharma over drug pricing probe

Alimta is Lilly's third biggest-selling drug. The Indianapolis-based drugmaker reported second-quarter sales of $577.8 million for the medicine.

Read Also: Biocon, Mylan launch biosimilar Ogivri for treatment of breast, stomach cancer in Australia